Cadence Bank Decreases Position in United Therapeutics Co. (NASDAQ:UTHR)

Cadence Bank decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,945 shares of the biotechnology company’s stock after selling 61 shares during the quarter. Cadence Bank’s holdings in United Therapeutics were worth $1,414,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the second quarter worth approximately $30,000. Innealta Capital LLC bought a new stake in United Therapeutics in the 2nd quarter worth approximately $33,000. USA Financial Formulas purchased a new stake in United Therapeutics during the 3rd quarter valued at $33,000. Finally, Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter valued at $33,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on UTHR. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. LADENBURG THALM/SH SH increased their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Stock Performance

UTHR stock opened at $378.13 on Thursday. The company has a market capitalization of $16.88 billion, a PE ratio of 16.61, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. The company’s fifty day moving average price is $366.18 and its 200-day moving average price is $333.84. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the previous year, the company earned $5.38 EPS. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. On average, research analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now owns 3,210 shares in the company, valued at approximately $1,108,766.10. This trade represents a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,227 shares of company stock worth $47,398,820 in the last quarter. 11.90% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.